Diabetes drug exenatide studied as potential cocaine addiction treatment
NCT ID NCT06252623
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test whether exenatide (Bydureon), a drug approved for type 2 diabetes, could safely reduce the urge to use cocaine. Researchers planned to give the drug or a placebo to people with cocaine use disorder and measure how many cocaine doses they chose to take. However, the study was withdrawn before enrolling any participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COCAINE USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Michael E. DeBakey VA Medical Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Weight-Loss drug may curb stimulant cravings, brain scans suggest
- Brain scans reveal how stress fuels cocaine relapse
- Scientists scan brains of cocaine users to uncover dopamine secrets
- Sound waves against addiction: ultrasound zaps cocaine cravings
- Magic mushroom compound tested to help people quit cocaine
- New drug tested against cocaine: no cure, just safety check